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Abstract A rapid and simple method for the simultaneous
detection and quantitation of amphetamine, methamphet-
amine, methylenedioxyamphetamine (MDA), methylene-
dioxymethamphetamine (MDMA) and methylenedioxy-
ethylamphetamine (MDEA) in human serum was devel-
oped and fully validated. Serum samples were extracted
with cyclohexane, derivatised with perfluorooctanoyl
chloride without prior evaporation of the solvent and anal-
ysed with gas chromatography-mass spectrometry (GC-
MS) in the selected ion monitoring mode (SIM). For
quantitation, deuterated analogues were used as the internal
standards. The limit of detection (LOD) and lower limit of
quantitation (LLOQ), bias and within-day and between-day
precision were determined. LODs calculated as the average
of the six calibration curves were below 5 ng/mL for all of
the measured compounds; LLOQs obtained in the same
manner were below 20 ng/mL, with the exception of MDA
(24.1 ng/mL). The coefficients of variation were below 7%
within series, 10% or less between series and the bias
was below 8% for all compounds. The calibration curves
were linear between the lower limits of quantitation and
800 ng/mL.
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Introduction
Amphetamines and their methylenedioxylated derivatives
belong to a group of the most frequently abused drugs. The
consumption of these substances as ‘‘party drugs,’’ con-
sidered to be harmless by most young people, is alarming,
especially if one considers their harmful effects on nerves,
the liver, the kidneys and the brain. Fatal poisonings with
and without the involvement of other toxicologically re-
levant substances have been reported [1–8]. Currently,
there is an increasing number of publications dealing with
drivers under the influence of methylenedioxyamphet-
amine-type drugs [9–13]. This development has affected
street traffic law in Germany. According to §24a StVG,
blood samples of supposedly drugged drivers are also
routinely analysed for the presence of amphetamine,
methylenedioxymethamphetamine (MDMA) and methy-
lenedioxyethylamphetamine (MDEA). It is planned to ex-
tend this list in the near future to include methamphetamine
as well. Furthermore, threshold values for prosecution are
intended to be introduced at a level of 25 ng/mL for each
of the amphetamines. In some forensic cases, the simulta-
neous determination of MDA, a metabolite of MDMA and
MDEA, is also of great interest.
Numerous methods for the detection of amphetamines
have been published in recent years (review of the years
1991 to 1997 [14]) using the following analytical tech-
niques: high-pressure liquid chromatography (HPLC)
[15–19], gas chromatography-mass spectrometry (GC-MS)
[15, 20–25], liquid chromatography-mass spectrometry
(LC-MS) [26, 27], capillary electrophoresis [28, 29],
capillary electrophoresis-mass spectrometry [30] and high-
field asymmetric waveform ion mobility spectrometry-
mass spectrometry [31]. Most of these methods, however,
involve evaporation of the extract prior to derivatisation.
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Besides being time-consuming, this step can lead to a more
or less pronounced loss of underivatised amphetamines
[32].
The aim of this study was to develop a rapid, reliable,
fully validated and low-priced method for the simultaneous
detection of different amphetamines, especially for con-
centrations in the range of the proposed threshold value of
25 ng/mL.
In 1993, Gjerde et al. [33] published a GC-MS-method
for the determination of amphetamine and methamphet-
amine in blood using derivatisation with perfluorooctanoyl
chloride (pentadecafluorooctanoyl chloride, PFOC). This
method, consisting of a simple liquid–liquid extraction
with direct derivatisation of the extract with perfluorooc-
tanoyl chloride without prior evaporation, was extended to
allow the simultaneous analysis of the methylenedioxylat-
ed derivatives MDA, MDMA, and MDEA as well. In
contrast to Gjerde et al. [33], who used only amphetamine-
d3 as the internal standard to quantitate amphetamine and
methamphetamine in this procedure, the corresponding
deuterated analogues of all target compounds were used.
The perfluorooctanoyl-derivatives of methylenedioxyam-
phetamines and their deuterated analogues with high and
characteristic ion masses have not been described yet. The
method was fully validated following DIN 32645 and ISO
5725 (according to the guidelines of the Society of Toxi-
cological and Forensic Chemistry, GTFCh) [32, 34, 35].
According to these guidelines, and in contrast to Gjerde
et al. [33], three instead of two ion masses were recorded in
single ion monitoring mode for each substance and the




Serum used for preparing spiked samples to determine
linearity, precision, accuracy, limit of detection (LOD) and
lower limit of quantitation (LLOQ) was obtained from a
volunteer who had given his formal consent.
Chemicals
Amphetamine sulphate, amphetamine-d3 sulphate, meth-
amphetamine hydrochloride, methylenedioxyamphetamine
(MDA) hydrochloride, methylenedioxymethamphetamine
(MDMA) hydrochloride and perfluorooctanoyl chloride
(pentadecafluorooctanoyl chloride, PFOC) were obtained
from Sigma-Aldrich (Deisenhofen, Germany). Methanolic
solutions of methylenedioxyethylamphetamine (MDEA),
methamphetamine-d8, MDA-d5, MDMA-d5 and MDEA-d6
were purchased in concentrations of 100 lg/mL from Ra-
dian/Promochem (Wesel, Germany). All standards were
obtained in a purity of 99% according to the certificate of
analysis of the manufacturer. Cyclohexane p.a. and sodium
hydroxide p.a. were purchased from Merck (Darmstadt,
Germany).
Preparation of the internal standard mixture
Methanolic solutions of methamphetamine-d8, MDA-d5,
MDMA-d5 and MDEA-d6 in concentrations of 100 lg/mL
were purchased and used as stock solutions. A standard
solution of amphetamine-d3 was prepared by dissolving
deuterated amphetamine sulfate in water to give a final
amphetamine-d3 concentration of 100 lg/mL. From these
stock solutions, a mixture of deuterated standards with
concentrations of 100 ng/mL (methamphetamine-d8,
MDA-d5, MDMA-d5) and 200 ng/mL (amphetamine-d3,
MDEA-d6), respectively, was prepared.
Preparation of spiked serum samples
Aqueous stock solutions were prepared giving concentra-
tions of 1 lg/mL and 100 ng/mL of each compound. These
solutions were used to add 0, 5, 10, 15, 20 and 25 ng of
each substance to 250 lL of blank serum, which corre-
sponds to concentrations of 0, 20, 40, 60, 80 and 100 ng/mL
serum. For the determination of the linearity range,
concentrations of 200, 400, 600, 800 and 1,000 ng/mL of
serum were also prepared using a stock solution containing
10 lg/mL of each compound.
Extraction procedure
To each spiked serum sample, 250 lL of the internal
standard mixture, 500 lL of aqueous sodium hydroxide
(5%, w/w) and 2 mL of cyclohexane were added. To
prevent the formation of an emulsion, the mixture was
gently vortex mixed or shaken by hand for about 30 s.
After centrifugation (5 min, 4,000 rpm), about 1.5 mL of
the organic layer were transferred to a glass tube. After
adding 50 lL of PFOC, the glass tube was tightly closed
with a Teflon-sealed screwcap. Derivatisation was per-
formed at 70 C for exactly 30 min. After evaporation of
the solvent at 30 C under a stream of compressed air,
the residue was dissolved in 20 lL of dried and distilled
ethyl acetate and transferred to a Teflon-sealed auto-
sampler vial with a conical 300-lL insert for GC-MS
analysis.
For the analysis of routine samples, 250 lL of serum
were extracted in the same way.
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Instrumentation
The GC-MS-system used was an Agilent 6890 gas chro-
matograph equipped with an Agilent 5973N mass selective
detector (Bo¨blingen, Germany), a Gerstel multipurpose
sampler MPS2 (Mu¨lheim an der Ruhr, Germany), a
Chrompack CP7860 column (CP-Sil 5 CB, 30 m·250 lm
i.d., 0.33-lm film thickness, Varian, Darmstadt, Germany)
and HPCHEM software (G1034 C version C.03.00, Agilent
Technologies, Waldbronn, Germany). Analyses were per-
formed under the following conditions: injector temperature
250 C, injection volume 1 lL in splitless mode, carrier gas
helium, pressure-programmed flow rate 1.0 mL/min and
MSD transferline 280 C. The oven was temperature-pro-
grammed as follows: the initial temperature of 80 C was
held for 1 min, increased to 180 C at a rate of 25 C/min,
then to 240 C at a rate of 10 C/min, then finally to 280 C
at a rate of 30 C/min, and was held at this temperature for
4 min. The total run time was 16.33 min. The ionisation
energy was 70 eV. The substances were measured in five
groups in the selected ion monitoring mode (SIM) mode, as
shown in Table 1, with a dwell time of 10 ms for each ion.
The bold ions were used for quantitation.
Validation of the method
Statistical data were determined according to the guidelines
of the Society of Toxicological and Forensic Chemistry
(GTFCh) [32, 34, 35]. These prescribe that the LOD und
LLOQ are calculated with a relative standard deviation
(1/k) of 33.3% and confidence levels of 90% and 99%,
respectively, using calibrator concentrations of 0, 20,
40, 60, 80 and 100 ng/mL. The validated method must
fulfil the following demands for all analytes: correlation
coefficient ‡0.98, LOD £15 ng/mL, LLOQ £25 ng/mL,
within-day precision, between-day precision and
bias £15%. Furthermore, the calibration should be linear
up to a concentration of 1,000 ng/mL and recovery should
be at least 50%.
All data were processed with the statistic software
Valistat (version 1.0, Arvecon GmbH, Walldorf, Germany)
[36], which is based on DIN 32645.
Selectivity
For the determination of method selectivity, ten different
blank serum samples from different sources were analysed
under the given GC-MS conditions to test for matrix
interferences. In addition, three blank serum samples
spiked with the internal standards were checked for the
absence of analyte ions.
Linearity and homogeneity of variance
Six independently prepared calibration rows with a con-
centration range of 0–100 ng/mL consisting of spiked
serum samples were analysed. Peak area ratios of the
analytes to the internal standards were calculated as a
function of the concentration. Additionally, in one series,
concentrations up to 1,000 ng/ml were measured to deter-
mine the maximum linearity range. The replicates of each
calibration level were checked for outliers via the Grubbs’
test and then averaged. Using the mean values, calibration
curves were checked for homoscedasticity (F test) and for
linearity (Mandel test). Additionally, each calibration curve
for each compound was tested for outliers and linearity,
again using the F test and Mandel test. The confidence
level used for each test was 99%.
Limit of detection and lower limit of quantitation
The limit of detection (LOD) and lower limit of quantita-
tion (LLOQ) for concentrations up to 100 ng/mL were
calculated according to DIN 32645 by interpreting the
characteristics of the calibration curves. The least intensive
ions (underlined in Table 1) were used for the determina-
tion of the LOD; the target ions (bolded in Table 1) were
very specific and were used for the determination of the
LLOQ. The LOD and LLOQ were calculated by using a
relative standard deviation (1/k) of 33.3% and confidence
levels of 90% (LOD) and 99% (LLOQ), respectively. The
Table 1 Groups of selected ions monitored (m/z) and exemplary






Amphetamine 6.35 118, 440, 441
Amphetamine-d3 6.34 121, 443, 444
Second group
Methamphetamine 7.00 118, 410, 454
Methamphetamine-d8 6.97 123, 413, 461
Third group
MDA 8.46 162, 440, 575
MDA-d5 8.44 167, 444, 580
Fourth group
MDMA 9.27 410, 454, 589
MDMA-d5 9.24 413, 458, 594
Fifth group
MDEA 9.57 162, 440, 468
MDEA-d6 9.54 165, 444, 474
a The bold ions were used as the target ions for quantitation and for
the determination of the lower limit of quantitation (LLOQ); for the
determination of the limit of detection (LOD), the least intensive ions
(underlined) were used
Accred Qual Assur (2007) 12:335–342 337
123
LOD and LLOQ shown in Table 2 were calculated as the
average of the results of the six calibration sets.
Precision and accuracy
For the determination of within-day precision, between-day
precision and accuracy (bias), spiked serum samples with
concentrations of 20 ng/ml and 80 ng/ml, respectively,
were analysed in duplicate on 8 days according to ISO
5725. The data were calculated by the analysis of variances
(ANOVA) between groups test.
Recovery
Blank serum samples were spiked at concentrations of
20 ng/mL and 80 ng/mL for each compound and extracted
as described above. Because the method requires only
250 lL of serum, this means that the samples contained 5 ng
or 20 ng of each compound, respectively. Following cen-
trifugation, as much as possible (usually between 1.5 mL
and 1.8 mL) of the organic layer was removed to determine
the maximum possible recoveries. After the addition of an
internal standard mixture in cyclohexane, the samples were
derivatised. Corresponding controls were prepared by add-
ing the internal standard mixture and 5 ng or 20 ng of each
compound to 1.5 mL of cyclohexane prior to derivatisation.
Results and discussion
Mass spectra and ion chromatograms
The mass spectra of amphetamine-PFO, methamphet-
amine-PFO, MDA-PFO, MDMA-PFO, MDEA-PFO and
their corresponding deuterated internal standards measured
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Fig. 1 Mass spectra of amphetamine-PFO, methamphetamine-PFO, MDA-PFO, MDMA-PFO, MDEA-PFO, amphetamine-d3-PFO, metham-
phetamine-d8-PFO, MDA-d5-PFO, MDMA-d5-PFO and MDEA-d6-PFO
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The ion chromatograms of a serum sample of a drugged
driver measured under the given conditions is shown in
Fig. 2.
Validation data
All measurements were performed under routine analyti-
cal conditions. No interfering peaks from the serum ma-
trix were observed. Peak purity and selectivity were
ensured.
Validation data referring to the lower concentration
range (up to 100 ng/mL) are presented in Tables 2 and 3.
For the six calibration runs, a homoscedastic data set
(constant variance over the whole range) was confirmed.
The calibration curves were linear for all substances
investigated. The LODs calculated as the average of the six
calibration curves were below 5 ng/mL for all of the
measured compounds. The LLOQs obtained in the same
manner were below 20 ng/mL, with the exception of MDA.
The values for precision and accuracy for extraction from
the serum samples are expressed as relative standard
deviation (RSD (%)). The coefficients of variation were
below 7% within series and 10% or less between series; the
bias was below 8% for all compounds (Table 2).
In one series, linearity was also determined for an ex-
tended calibration range using additional calibrators of 200,
400, 600, 800 and 1,000 ng/mL. Under these conditions,
the calibration curves were linear for concentrations up to
800 ng/mL (Table 4); the 1,000 ng/mL calibrator was the
first one to fail the linearity test.
Table 2 Limits of detection (LOD) and lower limits of quantitation
(LLOQ), accuracy (bias) and precision within and between series
according to DIN 32645 and ISO 5725 under the given statistical
parameters according to the guidelines of the Society of Toxicological













(ng/mL) (ng/mL) 20 ng/mL 80 ng/mL 20 ng/mL 80 ng/mL 20 ng/mL 80 ng/mL
Amphetamine 3.5 11.6 2.2 3.1 5.7 4.3 2.1 1.1
Methamphetamine 2.4 16.0 5.0 1.6 7.1 3.5 6.2 1.3
MDA 2.5 24.1 6.3 1.6 10.0 4.5 7.6 0.8
MDMA 4.3 13.1 3.3 1.7 7.0 3.8 5.5 1.6
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Fig. 1 continued
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The following mean recoveries were obtained at spiking
concentrations of 20 ng/mL and 80 ng/mL, respectively
(n=6): 88% and 80% for amphetamine (minima 78% and
65%), 92% and 79% for methamphetamine (minima 80%
and 73%), 86% and 75% for MDA (minima 76% and
62%), 98% and 84% for MDMA (minima 89% and 72%)
and 90% and 81% for MDEA (minima 77% and 69%). The
lower recoveries at higher concentrations suggest that
equilibrium has not quite been reached after an extraction
time of 30 s. The obtained recoveries are, however, suffi-
cient for the detection of even low concentrations of
amphetamines. Therefore, to keep the method fast and to
minimise the formation of emulsions, the extraction time
was kept at 30 s.
A comparison of the target values proposed by the
GTFCh and the observed values is given in Table 5. It
could be shown that the validation fulfilled all of the
mandatory regulations concerning the correlation coeffi-
cient, LOD, LLOQ, bias, within-day and between-day
precision for each analyte. The recommendation concern-
ing recovery was also completely met, whereas the cali-
bration curves turned out to be linear only up to 800 ng/
mL.
Conclusion and outlook
The reliability of analytical findings is a matter of great
importance in forensic and clinical toxicology, as the re-
sults may have wide legal consequences or lead to the
wrong treatment of a patient. So, at the very least, routine
analytical methods have to be validated, preferably using a
procedure which focusses on those parameters which are of
special importance for toxicologists [37]. The guidelines of
the Society of Toxicological and Forensic Chemistry
(GTFCh) meet these requirements.
By means of the rapid and simple method presented
above, amphetamine, methamphetamine, methylenedioxy-
amphetamine (MDA), methylenedioxymethamphetamine
(MDMA) and methylenedioxyethylamphetamine (MDEA)
can be quantitated simultaneously in serum, even at low
concentration levels. Using the corresponding deuterated
analogues of the target compounds as internal standards
resulted in lower values for the limit of detection (LOD),
the lower limit of quantitation (LLOQ) and precision data
for amphetamine and methamphetamine in comparison to
the published method of Gjerde et al. [33]. The validation
data show that the method yields very reliable and repro-
Table 3 Linearity parameters for a calibration range of 0–100 ng/mL (n=6). The results are given for the target ion (standard font) and the least
intensive ion (in italics)
Amphetamine Methamphetamine MDA MDMA MDEA
Correlation coefficients (ranges) 0.9996–0.9999 0.9991–0.9998 0.9989–0.9995 0.9996–0.9999 0.9996–0.9998
0.9984–0.9995 0.9988–0.9998 0.9993–0.9997 0.9967–0.9996 0.9998–0.9999
Standard error of the regression (ranges) 0.0015–0.0052 0.0075–0.0215 0.0132–0.0210 0.0050–0.0119 0.0038–0.0064
0.0066–0.0118 0.0099–0.0266 0.0131–0.0199 0.0144–0.0447 0.0041–0.0076
Slope (mL/ng) (mean±SDa) 0.0050 ± 0.0001 0.0123 ± 0.0005 0.0109 ± 0.0012 0.0109 ± 0.0004 0.0060 ± 0.0002
0.0049 ± 0.0003 0.0129 ± 0.0006 0.0129 ± 0.0006 0.0131 ± 0.0011 0.0087 ± 0.0003
y intercept (mean±SDa) –0.0005 ± 0.0081 –0.0003 ± 0.0292 0.0049 ± 0.0368 –0.0020 ± 0.0203 0.0013 ± 0.0112
0.0019 ± 0.0203 0.0002 ± 0.0363 –0.0043 ± 0.0380 0.0019 ± 0.0700 0.0000 ± 0.0153
Linear range (ng/mL) 3.5–100 2.4–100 2.5–100 4.3–100 1.4–100
a 95% confidence interval
Fig. 2 Ion chromatograms of a serum sample of a drugged driver
containing 577 ng/mL of MDMA, 38.3 ng/mL of MDA and 112 ng/mL
of MDEA measured under the given conditions
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ducible results. The in-situ derivatisation without prior
evaporation saves time and prevents losses of the highly
volatile underivatised amphetamines. The high recoveries
allow for an extremely short extraction time of about 30 s.
Large series of samples can be measured in a short time,
with low costs and only a small amount of serum sample is
needed.
During the past few years, the method has been effec-
tively employed in the routine analysis of hundreds of
serum samples from drivers suspected to be under the
influence of amphetamine or its derivatives and also for
proficiency tests. Furthermore, the method has been suc-
cessfully utilised for the analysis of hairs after alkaline
dissolution and of urine samples. These results suggest that
the presented method might also be used for the analysis of
other biological materials in forensic and clinical cases.
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